Research and Development

A Novartis drug which has been given breakthrough therapy designation by the FDA has demonstrated early promise in patients with …

GlaxoSmithKline is gambling millions of euros on an investigational drug in a bid to get an edge in the fight …

AstraZeneca is to exit development of a new rheumatoid arthritis drug, after Phase III trials produced disappointing results.The Anglo-Swedish firm …

Sanofi has consigned two investigational drugs to the corporate dustbin, preferring a $285 million dent in its coffers to continuing …

Boehringer’s pipeline has been boosted with the news that its investigational oral triple angiokinase inhibitor nintedanib plus chemotherapy, extends the …

Healthcare comms firm Vocera Communications has announced Brent Lang’s appointment as president and chief executive officer to the firm and …

Two ministers with responsibility for life sciences in the UK struck a cautious note over clinical trial transparency at an …

China-based biopharma products provider Sinovac Biotech has appointed vice president Nan Wang to be its chief financial officer. Previous CFO …

Europe has taken one step closer to increasing clinical trial transparency on the continent after MEPs voted yes on new …

Eli Lilly and Roche Diagnostics are among the key backers of a $360 million US life sciences research facility which …

Venture capitalist firm Avillion has announced the expansion of its leadership team with the appointment of Ramani Varanasi as chief …

Most people in the pharmaceutical industry, particularly in the UK, will be well-acquainted with Ben Goldacre by now. He published his …

UK-based contract development and manufacturing organisation SCM Pharma has strengthened its senior management team by recruiting a director. Paul Bradley …

Several post-marketing clinical trials of the blockbuster blood pressure drug Diovan may have been run by employees of the drug’s …

A new report by the National Audit Office says NICE should be given greater powers to access clinical trial data. …